Cover Image
市場調查報告書

A型流感感染疾病:全球臨床實驗趨勢

Influenzavirus A Infections Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 585573
出版日期 內容資訊 英文 301 Pages
訂單完成後即時交付
價格
Back to Top
A型流感感染疾病:全球臨床實驗趨勢 Influenzavirus A Infections Global Clinical Trials Review, H2, 2017
出版日期: 2017年10月31日 內容資訊: 英文 301 Pages
簡介

本報告提供A型流感感染疾病相關臨床研究最新趨勢分析,提供疾病·治療方法概要,及主要已開發國家 (G7各國)·新興國家 (E7各國) 的臨床實驗狀況,各地區、期、階段別進展,彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊,為您概述為以下內容。

目錄

  • 分析概要
  • 本報告分析範圍
  • 各地區的臨床實驗情形
    • 各國臨床實驗數量和平均實驗人數
      • 亞太地區主要5國的臨床實驗數量
      • 歐洲主要5國的臨床實驗數量
      • 北美主要國家的臨床實驗數量
      • 中東·非洲主要國家的臨床實驗數量
      • 中南美主要5國的臨床實驗數量
  • G7各國臨床實驗數量:感染疾病臨床實驗上A型流感感染疾病的比例
  • G7各國臨床實驗數量:各期
  • G7各國臨床實驗數量:各進展狀況
  • E7各國臨床實驗數量:感染疾病臨床實驗上A型流感感染疾病的比例
  • E7各國臨床實驗數量:各期
  • E7各國臨床實驗數量:各進展狀況
  • 各期臨床實驗數量
    • 進行中的臨床實驗:不同階段
  • 各進展狀況臨床實驗數量
  • 臨床實驗的目標達成情形
  • 一定期間所採用的實驗對象
  • 贊助商類別的臨床實驗數量
  • 有潛力的贊助商
    • A型流感感染疾病治療藥臨床實驗的主要參與企業
  • 有潛力的藥劑
  • A型流感感染疾病臨床實驗上最新趨勢
  • 有代表性的臨床實驗的簡介
  • 附錄
目錄
Product Code: GDHC4657CTIDB

GlobalData's clinical trial report, "Influenzavirus A Infections Global Clinical Trials Review, H2, 2017" provides an overview of Influenzavirus A Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Influenzavirus A Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Influenzavirus A Infections to Infectious Disease Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Influenzavirus A Infections to Infectious Disease Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Influenzavirus A Infections Therapeutics Clinical Trials 29
  • Prominent Drugs 30
  • Latest Clinical Trials News on Influenzavirus A Infections 31
  • Oct 12, 2017: Ventaleon reports clear clinical progress and additions to the Supervisory Board 31
  • Oct 04, 2017: BioCryst Announces RAPIVAB (peramivir injection) Presentations at IDWeek 2017 31
  • Sep 28, 2017: Shionogi to Highlight Research on S-033188, A Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at IDWeek 2017 32
  • Sep 26, 2017: Moderna Announces Publication in Molecular Therapy Characterizing Potent Immune Response Generated by Its mRNA Prophylactic Vaccines 32
  • Clinical Trial Profile Snapshots 33

Appendix 299

  • Abbreviations 299
  • Definitions 299
  • Research Methodology 300
  • Secondary Research 300
  • About GlobalData 301
  • Contact Us 301
  • Source 301

List of Tables

  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Influenzavirus A Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Influenzavirus A Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Influenzavirus A Infections Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Influenzavirus A Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14
  • Influenzavirus A Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Influenzavirus A Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
  • Influenzavirus A Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Influenzavirus A Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Influenzavirus A Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
  • Influenzavirus A Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Influenzavirus A Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Influenzavirus A Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Influenzavirus A Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Influenzavirus A Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Influenzavirus A Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Influenzavirus A Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Influenzavirus A Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures

  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Influenzavirus A Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Influenzavirus A Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Influenzavirus A Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Influenzavirus A Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 14
  • Influenzavirus A Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Influenzavirus A Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
  • Influenzavirus A Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Influenzavirus A Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Influenzavirus A Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
  • Influenzavirus A Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Influenzavirus A Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Influenzavirus A Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Influenzavirus A Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Influenzavirus A Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Influenzavirus A Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Influenzavirus A Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Influenzavirus A Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Influenzavirus A Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
  • GlobalData Methodology 300
Back to Top